Condition: Her-2 Negative Breast Cancer · HRR Gene Mutation · Sponsor: Ying Lin
This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.
This description comes directly from the study's public registry record.
Ying Lin, MD · +8602087755766 · linying3@mail.sysu.edu.cn
Xiaying Kuang, MD · +8602087755766 · kuangxy5@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital, Sun Yat-Sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05761470